1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Novo's Semaglutide Outperforms Lilly's Trulicity In SUSTAIN 7

 
• By Emily Hayes

Lilly's performance-based plans for Trulicity may be harder to sustain if Novo's competing once-weekly GLP-1 agonist semaglutide is approved in December, following superiority in a head-to-head diabetes study.

Diabetes

Novo Nordisk AS's investigational once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide is poised to give Eli Lilly & Co.'s once-weekly GLP-1 Trulicity a run for its money after demonstrating better performance for blood sugar lowering and weight loss in the head-to-head SUSTAIN 7 study of type 2 diabetes.

Semaglutide, which like Trulicity (dulaglutide) is given by injection, is now under review at the US FDA, with a December...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.